CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 39 enrolled
Drug / intervention
sunitinib malatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00392444
NCT00392444Phase 2Completed
CompareCT.gov

A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019) in Patients With Advanced Malignant Pleural Mesothelioma

National Cancer Institute (NCI)·interventional·Posted Oct 26, 2006·Updated May 21, 2014

In Brief

A Phase 2 clinical trial evaluating sunitinib malate for Advanced Malignant Mesothelioma and Recurrent Malignant Mesothelioma. Completed, enrolled 39 participants across 1 site.

Detailed Summary

This phase II trial is studying how well sunitinib works in treating patients with advanced malignant mesothelioma of the pleura. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignant Mesothelioma, Recurrent Malignant Mesothelioma
CountriesCanada
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 26, 2006
Enrollment StartFeb 1, 2007
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 19.7 years ago

Interventions

sunitinib malatedrug

Given orally